1 September 2024

VivaGel® condom receives regulatory approval in Canada

Melbourne, Australia; Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it had been granted a medical device license for the VivaGel® condom by the Canadian regulatory authority, Health Canada.

 

Starpharma’s marketing partner, Ansell (ASX: ANN), plans to launch the VivaGel® condom in Canada as soon as possible under the LifeStyles® Dual Protect™ brand.

 

The VivaGel® condom is a world-first product based on innovative Australian technology. It is the only condom of its type, providing barrier protection and incorporating the proprietary compound, astodrimer sodium (SPL7013, VivaGel®) in the condom lubricant.

 

Starpharma Chief Executive Officer, Dr Jackie Fairley, said, “The approval by Health Canada marks a further key commercial milestone for the VivaGel® condom product, and is very significant as the first North American approval for the product.”

 

Jeyan Heper, Ansell’s President and General Manager, Sexual Wellness Global Business Unit said “Ansell's mission is to provide innovative solutions for safety, well-being and peace of mind. We pride ourselves on our innovative products and the LifeStyles® Dual Protect™ condom is a great example of this, combining a high-quality condom with Starpharma's VivaGel®, a patented anti-viral technology.”

 

Regulatory reviews continue for the VivaGel® condom in a number of other geographic regions with further approvals anticipated in the coming months.

 

In May 2016, Starpharma and Ansell announced that VivaGel® condoms were provided to Australian athletes ahead of the Olympics in Rio de Janeiro. The antiviral condoms are also available for Australian athletes at the Paralympics.

 

About VivaGel®

VivaGel® has been proven in laboratory studies to inactivate up to 99.9% of HIV (human immunodeficiency virus), HSV (herpes simplex virus) and HPV (human papillomavirus), which are viruses that cause STIs.  VivaGel® was also recently shown in laboratory studies to have potent antiviral activity against the Zika virus at levels significantly below the concentration in the Dual Protect™ condom. It is now known that Zika virus can be sexually transmitted.

 

Customers in Canada can pre-order LifeStyles® Dual Protect™ condoms at www.lifestyles.com/dual-protect, as of Wednesday 14 September 2016.

 

Download ASX Announcement: VivaGel® condom receives regulatory approval in Canada ( pdf file, 924kb)


This contains certain forward-looking statements.

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.